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Abstract To date, weight loss surgeries are the most effective
treatment for obesity and glycemic control in patients with type 2
diabetes. Roux-en-Y gastric bypass surgery (RYGB) and sleeve
gastrectomy (SG), two widely used bariatric procedures for the
treatment of obesity, induce diabetes remission independent of
weight loss while glucose improvement after adjustable gastric
banding (AGB) is proportional to the amount of weight loss. The
immediate, weight-loss independent glycemic effect of gastric
bypass has been attributed to postprandial hyperinsulinemia
and an enhanced incretin effect. The rapid passage of nutrients
into the intestine likely accounts for significantly enhanced
glucagon like-peptide 1 (GLP-1) secretion, and postprandial
hyperinsulinemia after GB is typically attributed to the com-
bined effects of elevated glucose and GLP-1. For this re-
view we focus on the beneficial effects of the three most
commonly performed bariatric procedures, RYGB, SG,
and AGB, on glucose metabolism and diabetes remission.
Central to this discussion will be the extent to which the
effects of surgery are mediated by GLP-1. Better under-
standing of these mechanisms could provide insight to
development of novel therapeutic strategies for treatment
of diabetes as well as refinement of surgical techniques.
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1 The clinical role of weight-loss surgeries
Bariatric surgeries were originally categorized based on what
was commonly believed to be their mechanisms of action,
volume restriction, malabsorption or both. Malabsorptive pro-
cedures, such as biliopancreatic diversion and jejunoileal
bypass, are reconfigurations of the small intestine with the
intent of diminishing the area of intestinal mucosa available
for nutrient absorption. Procedures termed restrictive, such as
vertical banded gastroplasty or laparoscopic adjustable gastric
banding (AGB), limit the capacity of the stomach to accom-
modate food with an expected secondary restriction of calorie
intake. Among bariatric surgeries, Roux-en-Y gastric bypass
(RYGB), including components of restriction (a small gastric
pouch) and malabsorption (bypass of the stomach and prox-
imal portion of small intestine), was endorsed by National
Institutes of Health Consensus Development Panel as the ‘gold
standard’ procedure in 1991 because of its predictable high
weight-loss efficacy and low post-operative complication rates
[1]. Subsequently, this procedure has been the most commonly
performed bariatric surgery (60–80 %) in the US, with more
than 700,000 persons in the US over the last decade having
undergone RYGB [2]. In recent years sleeve gastrectomy (SG),
a procedure in which there is selective removal of the gastric
fundus and greater curvature of the stomach without intestinal
bypass, has also become popular, with comparable weight loss
to RYGB [3], from a technically easier procedure; SG com-
prised approximately one-third of bariatric procedures in 2012
[4]. While bariatric surgical procedures are still categorized as
restrictive or malabsorptive, this dichotomization has been
questioned recently [5] and there is certainly more to be learned
about the mechanisms of action of RYBG and SG.
While there are only limited data on the long-term results
of bariatric surgery, these have been generally positive. The
Swedish Obese Subjects trial compared groups of more than
2,000 obese subjects with bariatric surgery and a similar
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number with nonoperative treatment of obesity for 10 years.
In this cohort surgical treatment of obesity reduced mortality,
incident diabetes, and rates of myocardial infarction, stroke
and cancer [6]. In addition, short-term observational trials
have shown that weight loss following bariatric surgery is
associated with a reduction in key obesity-related metabolic
comorbidities, such as type 2 diabetes, hypertension, and
dyslipidemia [7]. Interestingly, some metabolic benefits of
bariatric surgery do not seem to be dependent on weight
loss, occurring soon after surgery before significant chang-
es in body weight. Notable among these are improvements
in diabetes, with better glycemic control and a need for
less diabetes treatment frequently observed in the imme-
diate postoperative period [8].
Recovery from diabetes following bariatric surgeries has
been well documented. In a prospective, longitudinal study
based on bariatric-specific data from 28,616 obese diabetic
patients, rate of remission or improvement in diabetes at 1 year
after RYGBwas 83% compared to 55% and 44% after SG and
AGB, with BMI reductions of ~15 kg/m2 compared to 12 and
7 kg/m2, respectively [7]. In keeping with these observational
studies, three randomized clinical trials have recently demon-
strated that a greater portion of patients with uncontrolled dia-
betes achieve target A1C levels at 1–2 years after RYGB com-
pared to those receiving lifestyle and/or medical interventions
alone [9–11]. Compared to AGB, RYGB is more effective in
inducing remission of metabolic conditions such as diabetes,
hypertension and dyslipidemia. This is in keeping with greater
effectiveness in weight loss as reported from a recent prospec-
tive multi-central study of 2,348 patients with type 2 diabetes in
the US [12]. Preliminary evidence suggests that RYGB may be
more effective for treating diabetes than SG [13] with longer-
lasting effects even when weight reduction is comparable [14].
2 Weight-loss independent glycemic effect of bariatric
surgeries
It is well recognized that weight loss whether induced by life
style interventions or a bariatric surgery improves glucose
tolerance, mainly by enhancing insulin sensitivity and im-
proving fasting glucose kinetics [15–17]. Therefore, some of
the profound reduction in mean blood glucose among persons
with type 2 diabetes who have bariatric procedures can be
attributed to surgical-induced weight loss. In fact, improve-
ment in glucose homeostasis with gastric restrictive surgeries,
similar to life-style interventions, occurs over weeks to
months in parallel with, and proportional to, the amount of
weight loss [18]. However, much of the effect of RYGB and,
to lesser degree, SG, is immediate and partly independent of
the amount of weight loss [17, 19–21].
In a longitudinal prospective study of subjects with type 2
diabetes and recent RYGB, the need for antidiabetic
medications was eliminated in more than 30 % at the time of
discharge from hospital [22]. The likelihood of diabetes re-
mission was inversely related to the duration of diabetes
suggesting that factors related to shorter exposure to hyper-
glycemia, e.g. healthier islet β-cells, respond better to the
surgical treatment. This immediate, weight-loss independent
glucose-lowering effect of RYGB has been attributed to alter-
ations in postprandial glucose homeostasis as a result of
enhanced nutrient fluxes [23, 24] and enteroinsular signaling
[25, 26].
After GB, and to lesser extent after SG, meal ingestion
results in earlier and higher peaks of glucose as well as rapid
declines to a lower glucose nadir. In parallel there is a similar
pattern of insulin and GLP-1 secretion with earlier and larger
peaks compared to people without surgery [20, 25, 27–30]
(Fig. 1). This pattern is due in part to more rapid transit of
nutrients into the small intestine from the restricted gastric
compartments that inherent to these surgeries. Thus, there are
large fluxes of nutrients onto the absorptive surface of the gut,
and glucose into the splanchnic circulation [23, 24, 30]. Gas-
tric emptying in individuals with an intact GI tract is tightly
regulated [31, 32] due in part to feedback from small intestinal
signals activated by luminal nutrients [31]. While gastric
banding seems to have no effect on nutrient emptying [33],
GB and SG are associated with an increased pace of nutrient
passage through the gastric pouch/stomach into the small
intestine [34, 35]. Emptying of the stomach pouch in individ-
uals after GB is about 2–3 times faster than that in non-
surgical healthy controls for both liquid and solid markers
[36]. Following GB, rapid pouch emptying is attributed pri-
marily to the size of the gastric outlet and the pressure gradient
across the gastrojejunostomy [37], and is likely to be indepen-
dent of neural or hormonal factors. Compared to non-surgical
subjects, SG also leads to a 1.5–2 fold decrease in the half-
time of gastric emptying, and increased small intestinal transit
time for both liquid and solid food [38, 39], which is smaller
than what has been reported after GB.
Given that procedures utilizing the foregut bypass have
been described to improve glycemic control in non-obese
[40–42] or mildly obese individuals [43], independent of
weight loss, these procedures have been investigated as pri-
mary treatments for diabetes [44]. Glycemic improvement
measured as the average A1C reduction at 6–21 months after
some version of foregut bypass ranged from 2 to 4 % [40–42].
RYGB led to A1C reduction of 3 % at 1 y in 66 mildly obese
patients with uncontrolled long lasting type 2 diabetes, and
glycemic control was maintained up to 5 years, [43]. In these
clinical studies, the amount of weight loss did not correlate
with indices of glycemic improvement after surgery [41, 43].
The substantial impact of gastric bypass on glucose
metabolism is exemplified by the syndrome of postprandial
hyperinsulinemic hypoglycemia, which occurs in a small sub-
set of subjects, but has not been reported after restrictive
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bariatric procedures or SG. Affected patients have larger meal-
derived glucose appearance along with larger insulin and
GLP-1 secretion compared to the background population
who have undergone RYGB [45] (Fig. 2). The exaggerated
insulin response in these individuals is not significantly related
to the amount of weight loss or insulin sensitivity [46].
3 Enteroinsular activity after bariatric surgeries
It has been recognized that postprandial glucose metabolism
and islet function are tightly regulated by gut factors,
collectively termed incretins. The greater insulin secretion
in response to oral compared to intravenous (IV) glucose
administration is termed the incretin effect and provides a
quantitative measure of the effects of insulinotropic factors
initiated by meal ingestion/absorption. While the hormonal
component of the enteroinsular axis, principally the two gut
hormones, glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide 1 (GLP-1), is better under-
stood, the incretin effect also contains direct nutrient and
neural stimulation [47].
An improved beta-cell response to meal ingestion has been
reported as early as 1 week after RYGB [20]. Moreover, this
effect is specific to enteral nutrients, since the insulin response
to intravenous glucose, which has no effect on the incretin
effect, is not changed by surgery [26, 48, 49]. One possibility
that is frequently raised to explain the augmentation of insulin
secretion after RYGB, and potentially the weight-loss inde-
pendent improvement in glucose metabolism and diabetes, is
increased action of the incretins. In this model, delivery of
nutrients directly into the intestine leads to an increased se-
cretion of insulinotropic hormones from the GI tract that
parallels the higher rates of nutrient flux after RYGB. In fact,
secretion of both incretins is changed by surgery. GIP levels
shift upwards and to the left, consistent with a more rapid
response to eating, although the 2–3 h integrated values of
GIP are no different from individuals without surgery [46].
However, GLP-1 secretion after RYGB and SG is substan-
tially enhanced. Both early and overall GLP-1 responses to
test meals are higher, sometimes as much as 10-fold, those
of un-operated controls or subjects with gastric restrictive
surgery [23, 45, 50–52]. This effect can also be seen in
subjects studied before and after surgery [25, 53]. Compared
to controls, SG also enhances GLP-1 secretion but to lesser
extent than RYGB [14, 29] (Fig. 1).
GLP-1 is a product of the proglucagon gene that is synthe-
sized by intestinal endocrine L-cells, located with greatest
density in the ileum and colon. GLP-1 is secreted shortly after
nutrient ingestion, and plasma levels increase 2–3 fold in
Fig. 1 Blood glucose (A), insulin (B), and GLP-1 (C) response to liquid meal or oral glucose ingestion in non-surgical healthy controls and those after
AGB, SG, and RYGB [29, 46, 51]. Data were adjusted for baseline values
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healthy individuals [54]. Once released to the circulation,
GLP-1 is rapidly metabolized by a widely distributed serine
protease, dipeptidyl peptidase IV (DPP-4) [55], such that the
half-life of bioactive GLP-1 is less than 2 min in humans.
Because of the drainage of the gut, concentrations of GLP-1 in
the hepatic portal vein are approximately twice those in
peripheral circulation [56]. GLP-1 actions are mediated
through a receptor specific for GLP-1 (GLP-1r), expressed
in different tissues, including pancreatic islet cells, some
brain areas (hypothalamus, hindbrain and midbrain), portal
vagal afferent nerves, gastric mucosal cells, lung, heart
and kidney. Exogenous administration of GLP-1 improves
glucose tolerance by increasing insulin secretion [57], sup-
pressing glucagon secretion [58], delaying gastric emptying
[59], decreasing endogenous glucose production [60].
While the underlying mechanisms by which gastric bypass
surgeries or SG enhance the GLP-1 response is not totally
understood, the rapid passage of nutrients into the intestine
could partially account for this effect [61, 62]. However,
postprandial hyperinsulinemia after GB and SG can likely
be attributed to the combined effects of elevated glucose and
GLP-1. RYGB has shown to increase incretin effect [25]
independent of weight loss while the magnitude of the incretin
effect after SG has not been clearly defined.
4 The role of GLP-1 on glucose metabolism after bariatric
surgeries
The elevated concentrations of GLP-1 that are a consistent and
persistent effect of RYGB [63] has led to considerable spec-
ulation that this glucoregulatory peptide could have a central
role in post-surgical effects. Recent work in humans supports
this proposal. However, there are now several preclinical
studies using mouse models with GLP-1 receptor deletions
that raise questions as to the necessity of GLP-1 signaling after
bariatric surgery. There have been great advances in the
development of surgical models in rodents and both RYGB
and SG can be replicated with fidelity in small animals,
including reliable weight loss, improved glucose tolerance
and increased plasma GLP-1. GLP-1 receptor knockout
mice lost equivalent weight and had comparable glucose
tolerance to control animals after RYGB [64] and SG [65].
While these studies have the strength of a well-defined
molecular mechanism to isolate the effect of GLP-1 signaling,
there are several caveats that should be considered when
extending the results to humans. However, animals with
developmental gene deletions and lifelong absence of
GLP-1 signaling may develop compensations that allow
them to have apparent normal function. Thus, the disparate
results in humans and mice on the role of GLP-1 to
mediate effects of bariatric surgery require more study for a
definitive conclusion.
The physiologic actions of endogenous GLP-1 on glucose
metabolism have been studied using continuous infusion of a
potent GLP-1r antagonist, exendin-[9–39], Ex-9. Post-meal
glucose homeostasis is tightly regulated as a result of GLP-1
action since elimination of this action causes a deterioration of
glucose tolerance [66]. However, interpretation of the effect of
GLP-1r blockade on insulin response during meal or oral
glucose studies is complicated due to increased glycemia as
a result of Ex-9 infusion. Studies with glucose or meal inges-
tions during fixed blood glucose concentrations with a
Fig. 2 Blood glucose (A), systemic appearance of ingested glucose
(RaOral) (B), and GLP-1 (C) levels during meal tolerance test in patients
with hypoglycemia after RYGB and those without
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hyperglycemic clamp has demonstrated that blocking endoge-
nous GLP-1 reduces postprandial insulin secretion by 30-40 %
and increases glucagon release [67]. These findings indicate that
endogenous GLP-1 has a significant insulinotropic effect in
healthy humans, and important glucagonostatic properties as
well. Of note, the relative contribution of the GLP-1 effect to
postprandial insulin secretion is similar in patients with well-
controlled T2DM and age- and weight-matched controls [68],
despite an absolute reduction in beta-cell function in the diabetic
individuals. The insulintropic effect of GLP-1 does not seem to
be mediated through alteration in gastric emptying since endog-
enous GLP-1, unlike pharmacological levels of GLP-1 or GLP-
1 agonists, has only modest effects on the rate of nutrient
passage from the stomach to the small intestine [67–69].
The effect of GLP-1 on insulin secretion after gastric bypass
surgery was examined using Ex-9 infusion during a liquid
mixed-meal tolerance study while blood glucose levels were
maintained at 240 mg/dl in non-diabetic individuals with and
without history of gastric bypass surgery [26] (Fig. 3). Surgical
subjects had greater insulin secretion to nutrient ingestion com-
pared to the controls and this effect was partly attributed to
exaggerated endogenous GLP-1 action in these individuals
since Ex-9 reduced insulin secretion by 33±4 % in the RYGB
group compared to 16±5 % in the controls. Blocking GLP-1r
resulted in larger glucagon response to meal ingestion in both
surgical and non-surgical subjects, suggesting that the
glucagonostatic effect of GLP-1 is also preserved after RYGB.
Systemic appearance of ingested d-xylose was not influenced
by GLP-1r blockade in either group, demonstrating that nutri-
ent passage from the stomach/gastric pouch to small intestine is
not affected as a result of ex-9 during a hyperglycemic clamp.
This was the first study to address the direct role of endogenous
GLP-1 on islet function in RYGB and the results confirmed the
hypothesis that the greater circulating GLP-1 levels after sur-
gery lead to greater GLP-1 action. Extension of these experi-
ments to meal studies confirmed these findings, with RYGB
subjects showing a larger effect of GLP-1r antagonism on
glycemic excursion than non-operated controls (change in
AUCGlucose(3hr): 37±12 % versus 14±12 % [45]). In this study,
where postprandial glucose was not clamped, Ex-9 shortened
the time to reach the peak of oral glucose appearance in both
groups, indicating more rapid nutrient passage as a result of
blocking GLP-1 action. In keeping with these findings, other
investigators have reported a larger increase in the postprandial
glycemia in surgical subjects compared to non-operated con-
trols (change in AUCGlucose(6hr): ~45% vs. ~24%) as a result of
Ex-9 infusion [45]. Blocking GLP-1r in this study increased the
rate of radiolabeled meal transit in RYGB subjects indicating
that GLP-1 regulates the emptying of the gastric pouch after
surgery.
The role of enhanced GLP-1 action in the antidiabetic effects
of RYGB was investigated by two independent groups using
different methods. In the first study [70], 9 patients with well
controlled diabetes consumed liquid mixed-meals with and
without infusion of Ex-9 before surgery, and 1 week and
3 months after surgery. Eight of these subjects were taking
antidiabetic medications (metformin alone or in combination
with insulin secretagogues or insulin) before surgery, but none
required anymedication after surgerywith normal HbA1c levels
by 3 months. After surgery the subjects had earlier and larger
glycemic excursions, with left-shifted insulin responses and
increased β-cell glucose sensitivity. Ex-9 infusion increased
glucose levels both before and after surgerywith a 30% increase
in the 4 h glycemic response. Blocking GLP-1r diminished the
insulin secretion to levels similar to those before surgery, indi-
cating that a major portion of the glycemic benefit of RYGB is
attributable to the insulinotropic effect of endogenous GLP-1.
Similar to previous studies, Ex-9 increased glucagon and the
beneficial effects of GLP-1 action was not dependent on chang-
es in gastric emptying. A second study compared 8 patients with
T2DM resolved after RYGB, and 7 age-matched and leaner
non-diabetic controls, using Ex-9 to block GLP-1r during a
liquid test meal [71]. The overall glucose response
(AUCGlucose(2hr)) to the test meal was greater in the surgical
subjects, as were their insulin responses. Ex-9 increased post-
meal glycemia similarly in both groups similarly, ~10 %, but
with greater suppression of insulin secretion in the surgical
subjects. Taken together these findings demonstrate that the
contribution of endogenous GLP-1 to postprandial insulin se-
cretion is enhanced after RYGB, and improvement in postpran-
dial glucose metabolism after surgery is at least partly due to this
effect. By extension, it is plausible that enhanced GLP-1-
stimulated insulin secretion is even further exaggerated in indi-
viduals who suffer from postprandial hyperinsulinemic hypo-
glycemia. Blocking GLP-1r corrected hypoglycemia in a group
of subjects with GB-related postprandial neuroglycopenic hy-
poglycemia [45], and the contribution of GLP-1 to postprandial
insulin secretion was larger in affected individuals compared to
asymptomatic RYGB subjects. This finding is consistent with a
significant role for GLP-1 action in pathogenesis of post-GB
hypoglyemia. In this cohort, subjects with hypoglyemia after
GB also had larger meal-derived glucose appearance compared
to those without hypoglycemia, implying that increased nutrient
flux contributes to enhancedGLP-1 action.While elimination of
GLP-1 action has a larger effect on glycemia among subjects
after RYGB, which is accentuated in those with the
hyperinsulinemic hypoglycemia syndrome, it is not clear wheth-
er the increasedGLP-1 action is due to larger GLP-1 secretion or
greater beta-cell responsiveness to GLP-1.
The level of expression of islet GLP-1 receptors in pancre-
atic tissue samples obtained from 6 subjects with RYGB-
related hypoglycemia did not differ from non-surgical controls
[72]. Moreover, we have found that β-cell sensitivity to a step-
wise incremental infusions of GLP-1 or GIP are not increased in
non-diabetic subjects after GB compared to BMI- and age-
matched non-surgical controls with normal glucose tolerance
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(M Salehi, unpublished). Based on these preliminary findings,
enhanced GLP-1 action after GB does not seem to be due to
increased beta-cell responsiveness to GLP-1. However, circulat-
ing levels of GLP-1 do not seem to entirely account for the high
level of GLP-1 action in bariatric subjects since plasma GLP-1
concentrations do not correlate with the GLP-1-induced insulin
response [26]. The portal-systemic gradient in glucose andGLP-
1 levels has been previously reported [56]; it is possible that the
gradient is larger after reconfiguration of GI tract and variable
among surgical individuals given the anatomical differences.
The role of the enteroinsular axis in postprandial glucose
homeostasis has not been studied in human after SG but SG
appears to have similar effects on glucose, insulin, and GLP-1
responses to meal ingestion as GB [29], only smaller [14].
In summary, the bulk of experimental data from humans
support a role for increased GLP-1 secretion and action to
account for the characteristic patterns of insulin secretion and
glucose regulation seen after RYGB and possibly SG. It is
important to note that there is virtually no data from human
studies to implicate or rule out a role for increased GLP-1 in
the anorectic and weight loss effects of bariatric surgery.
Improvements in assays for plasma GLP-1 and the availability
of a well-defined GLP-1 receptor agonist will allow more
refined hypotheses, such as the role of inter-individual
Fig. 3 Blood glucose (A), insulin secretion rates (B), and glucagon (C) before and after meal ingestion during hyperglycemic clamp studies with
(dashed line) and without (solid line) GLP-1r blockade
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variability in sensitivity to GLP-1, to be explored in bariatric
patients. This area of research is likely to provide a valuable
foothold for extending the understanding of physiologic
mechanisms in weight loss surgery and for development of
novel therapeutic approaches for treatment of diabetes.
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